Back
65· Active
Health & Science2d 12h ago
The FDA has granted De Novo marketing authorization to DermaScan AI, the first consumer-grade handheld device for detecting malignant melanoma and basal cell carcinoma.
Silver Spring, Maryland, USA
Who
U.S. Food and Drug Administration (FDA)
What
The FDA has granted De Novo marketing authorization to DermaScan AI, the first consumer-grade handheld device for detecting malignant melanoma and basal cell carcinoma.
When
Sat, 06 Jun 2026 21:50:05 GMT · 2d 12h ago
Where
Silver Spring, Maryland, USA · 39.0232°N, 77.0177°W
Why
Following clinical trials with a 94% sensitivity rate, the agency determined the tool meets safety standards for pre-screening common skin cancers at home.
The Frontline Impact
How this affects you
This expands accessibility for early cancer detection, potentially reducing the burden on dermatology clinics while allowing users to monitor suspicious moles more accurately than with visual inspection alone.
Story chain
1 event in this threadNo related history yet — this is the origin event.
Verified Sources & Citations
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.